Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

804 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees.
Andreano E, Paciello I, Marchese S, Donnici L, Pierleoni G, Piccini G, Manganaro N, Pantano E, Abbiento V, Pileri P, Benincasa L, Giglioli G, Leonardi M, Maes P, De Santi C, Sala C, Montomoli E, De Francesco R, Rappuoli R. Andreano E, et al. Among authors: rappuoli r. Nat Commun. 2022 Jun 13;13(1):3375. doi: 10.1038/s41467-022-31115-8. Nat Commun. 2022. PMID: 35697673 Free PMC article.
Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses.
Alberini I, Del Tordello E, Fasolo A, Temperton NJ, Galli G, Gentile C, Montomoli E, Hilbert AK, Banzhoff A, Del Giudice G, Donnelly JJ, Rappuoli R, Capecchi B. Alberini I, et al. Among authors: rappuoli r. Vaccine. 2009 Oct 9;27(43):5998-6003. doi: 10.1016/j.vaccine.2009.07.079. Epub 2009 Aug 7. Vaccine. 2009. PMID: 19665606 Clinical Trial.
One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies.
Faenzi E, Zedda L, Bardelli M, Spensieri F, Borgogni E, Volpini G, Buricchi F, Pasini FL, Capecchi PL, Montanaro F, Belli R, Lattanzi M, Piccirella S, Montomoli E, Ahmed SS, Rappuoli R, Del Giudice G, Finco O, Castellino F, Galli G. Faenzi E, et al. Among authors: rappuoli r. Vaccine. 2012 Jun 8;30(27):4086-94. doi: 10.1016/j.vaccine.2012.04.020. Epub 2012 Apr 19. Vaccine. 2012. PMID: 22521851
Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2.
Ahmed SS, Volkmuth W, Duca J, Corti L, Pallaoro M, Pezzicoli A, Karle A, Rigat F, Rappuoli R, Narasimhan V, Julkunen I, Vuorela A, Vaarala O, Nohynek H, Pasini FL, Montomoli E, Trombetta C, Adams CM, Rothbard J, Steinman L. Ahmed SS, et al. Among authors: rappuoli r. Sci Transl Med. 2015 Jul 1;7(294):294ra105. doi: 10.1126/scitranslmed.aab2354. Sci Transl Med. 2015. PMID: 26136476 Clinical Trial.
Vaccine Evolution and Its Application to Fight Modern Threats.
Andreano E, D'Oro U, Rappuoli R, Finco O. Andreano E, et al. Among authors: rappuoli r. Front Immunol. 2019 Jul 25;10:1722. doi: 10.3389/fimmu.2019.01722. eCollection 2019. Front Immunol. 2019. PMID: 31404139 Free PMC article. Review.
SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma.
Andreano E, Piccini G, Licastro D, Casalino L, Johnson NV, Paciello I, Dal Monego S, Pantano E, Manganaro N, Manenti A, Manna R, Casa E, Hyseni I, Benincasa L, Montomoli E, Amaro RE, McLellan JS, Rappuoli R. Andreano E, et al. Among authors: rappuoli r. bioRxiv [Preprint]. 2020 Dec 28:2020.12.28.424451. doi: 10.1101/2020.12.28.424451. bioRxiv. 2020. PMID: 33398278 Free PMC article. Updated. Preprint.
Vaccinology in the post-COVID-19 era.
Rappuoli R, De Gregorio E, Del Giudice G, Phogat S, Pecetta S, Pizza M, Hanon E. Rappuoli R, et al. Proc Natl Acad Sci U S A. 2021 Jan 19;118(3):e2020368118. doi: 10.1073/pnas.2020368118. Proc Natl Acad Sci U S A. 2021. PMID: 33431690 Free PMC article.
804 results